| I. | Component Collection, including complications |
| II. | Serologic and Infectious Disease Testing of Donor Units |
| Tests routinely performed | |
| III. | Preparation, Storage, and Release of Blood Components and Derivatives |
| Storage lesions of components | |
| IV. | Compatibility Testing of Red Cells and Components |
| Accurate patient identification | |
| Use of automated equipment for pre-transfusion testing | |
| Serologic confirmation of donor blood ABO/Rh | |
| Pre-transfusion testing of patient blood | |
| Selection of compatible blood and components for transfusion | |
| Crossmatch | |
| Special considerations for neonates | |
| Selection of compatible blood and components in special circumstances | |
| Urgent requirements for blood and components | |
| V. | Indications for Use and Administration of Components and Derivatives, (including RBCs, platelets, plasma, factor concentrates) |
| Leukocyte-reduction benefits | |
| Indications for irradiated components | |
| Indications for blood warmers | |
| Indications for filters | |
| Compatible fluids | |
| VI. | Special Transfusion Situations |
| ADAMTS-13 and TTP | |
| Criteria for administration of Rh immune globulin | |
| Massive transfusion | |
| Neonatal alloimmune thrombocytopenia purpura | |
| VII. | Therapeutic Apheresis and Phlebotomy |
| Established indications | |
| American Society for Apheresis Guidelines | |
| VIII. | Diagnosis and Management of Non-Infectious Complications of Transfusion |
| TRALI—etiology, clinical signs and symptoms | |
| TACO | |
| Allergic transfusion reactions | |
| Basic evaluation and differential diagnosis of fever, hypotension, dyspnea and/or other signs and symptoms during a blood component transfusion. | |
| When to stop a transfusion and when it is safe to continue | |
| IX. | Transfusion Transmitted Infectious Disease |
| Limiting and detecting bacterial contamination in platelets | |
| Current risks in the
United States of transmission of: HIV, HBV, and HCV | |
| Other infectious complications of transfusion (e.g. West Nile Virus, Chagas disease, HTLV, CMV, bacteria) | |
| X. | Management |
| Updates to AABB Standards | |
| Updates to FDA Guidance and Regulations | |
| Transfusion committee composition and responsibilities | |
| References |